A investpharm, UAB - financials and debts

Company age: 4 y. 8 mo.

Update

A investpharm - Company finances

EUR
2022
From: 2022-01-20
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue - 18,206 23,500 8,312
Profit before tax -363 585 2,667 375
Net profit -363 574 2,534 315
Equity 2,137 2,711 5,245 5,560
Liabilities 363 9,819 247 7,635
Non-current assets 0 0 0 0
Current assets 2,500 12,530 5,492 13,195
Total assets 2,500 12,530 5,492 13,195
Taxes paid
STI taxes - - 11 133
Financial indicators
Revenue change y/y - - +29.1% -64.6%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -14.5% 4.6% 46.1% 2.4%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. -17.0% 21.2% 48.3% 5.7%
Profit margin Net profit margin. Shows the overall profitability of the company. - 3.2% 10.8% 3.8%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - 3.2% 11.3% 4.5%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.2 3.6 0.0 1.4
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - 18,206 23,500 8,312

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

A investpharm - Social security debts

From To Debt, €
2026-02-18 2026-02-22 0.75
2025-09-16 2025-09-22 0.90
2024-12-17 2024-12-20 1.37

A investpharm - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
A investpharm, UAB (company code 305987591) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €8.3K and recorded net profit of €315, resulting in a profit margin of 3.8%. This was a weaker year than 2024, when revenue reached €23.5K and net profit €2.5K, after €18.2K of revenue and €574 of net profit in 2023. Over the two-year period to 2025, revenue declined by 54.3%, and the year-on-year drop in 2025 was 64.6%. Despite the lower turnover, the balance sheet remained positive, with total assets of €13.2K, equity of €5.6K and liabilities of €7.6K at the end of 2025. Key ratios for 2025 show a return on equity of 5.7%, return on assets of 2.4%, debt-to-equity of 1.37 and asset turnover of 0.63x. Revenue per employee was €8.3K, with profit per employee of €315.